WHAT DOES IT MEAN TO BE A HIGH RISK REGISTRY MEMBER?

If you consent to be a member of the Registry, you will be asked to complete an initial medical history questionnaire and twice-yearly update questionnaires.

Your identity as a registry member and all of the information you provide will be kept confidential by Creighton University.

Researchers performing early cancer detection studies will submit proposals to the Registry whenever they wish to recruit study participants with gene mutations for hereditary cancer.

When a registry member is identified as eligible for a research study, the Registry will send information to the registry member about the project and its risks, benefits and associated procedures.

As a registry member, you have the opportunity to choose whether to participate or not after reviewing the particular requirements associated with each study.

EARLY DETECTION RESEARCH NETWORK MEMBERS

DEVELOPMENT LABORATORIES
University of Colorado Health Sciences Center
Yale University
Georgetown University
University of South Florida
Northwestern University
Johns Hopkins University
University of Maryland
University of Michigan
Genetica Inc.
Mount Sinai School of Medicine
Duke University Medical Center
University of Washington
Thomas Jefferson University
University of Pittsburgh
University of Texas Southwestern Medical Center
Eastern Virginia Medical School
University of Texas M.D. Anderson Cancer Center

VALIDATION LABORATORIES
University of Alabama
University of California, Los Angeles
National Institute of Standards and Technology

CLINICAL CENTERS
Creighton University Hereditary Cancer Institute
Center for Disease Control and Prevention
Brigham and Women’s Hospital
Johns Hopkins University
University of Michigan
New York University
University of Texas M.D. Anderson Cancer Center
University of Texas Health Sciences Center

DATA MANAGEMENT CENTER
Fred Hutchinson Cancer Research Center

FOR MORE INFORMATION
Contact the EDRN Registry at Creighton University
1-800-648-8133 ext. 3189 OR
http://medicine2.creighton.edu/EDRN-Registry
A program sponsored by The National Cancer Institute
DIVISION OF CANCER PREVENTION
The National Cancer Institute (NCI) is dedicated to defeating cancer. To achieve its mission, the Institute explores new fields of research and creates new ways of bringing promising research findings into medical practice for the benefit of all.

Cancer detection at its earliest stage is a major focus for NCI research. NCI’s Division of Cancer Prevention has brought together a group of the country’s top researchers to concentrate their efforts on early cancer detection. This group is called the Early Detection Research Network (EDRN)*.

The purpose of the EDRN is to identify the initial changes, called biomarkers, that occur as cancer develops and to shorten the time it takes to use biomarkers for routine cancer risk assessment and detection.

To translate newly emerging scientific knowledge into practical clinical tests, this multi-center network will:

- Discover new cancer biomarkers
- Develop early detection tests using promising biomarkers
- Conduct large studies to validate the clinical usefulness of new tests
- Rapidly move useful EDRN findings into routine medical practice

Using these clinical tests, physicians can:

- Identify people at risk for developing cancer before they develop the disease
- Treat cancer at its earliest stages
- Focus on prevention

This endeavor, one of unprecedented change and scope, provides a promising opportunity for improving medical practice.

*The members of this network are listed on the back panel of this brochure.